Adverum Biotechnologies Inc expected to post a loss of $1.40 a share - Earnings Preview

Adverum Biotechnologies

07/05/2024 12:02

* Adverum Biotechnologies Inc  ADVM.OQ   ADVM.O  is expected
to show a fall in quarterly revenue when it reports  results on
May 9 (estimated) for the period ending March 31 2024
    * The Redwood City California-based  company is expected to
report
a 97.6% decrease in revenue to $85 thousand from $3.6 million a
year ago, according to the mean estimate from 6 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Adverum Biotechnologies
Inc is
for a loss of $1.40 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 3.1%
in the last three months. ​
    * Wall Street's median 12-month price target for Adverum
Biotechnologies Inc is $35.00​, above​ its last closing price
of $10.66. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -3.35       -3.37      -2.30     Beat    31.7
 Sep. 30 2023  -3.06       -3.15      -3.30     Missed  -4.7
 Jun. 30 2023  -3.12       -3.29      -3.10     Beat    5.7​
 Jan. 1 0001   -3.20       -3.20      -2.90     Beat    9.5
 ​​Jan.        -3.72       -3.62      -3.30     Beat    8.9
 1 0001                                                 
 Sep. 30 2022  -3.03       -3.45      -4.00     Missed  -15.9​
 Jun. 30 2022  -3.58       -3.40      -4.40     Missed  -29.4
 Jan. 1 0001   -3.19       -3.10      -3.80     Missed  -22.6
 This summary was machine generated May 7 at 11:01 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)